Epoetina Alfa Nel Trattamento Dell'Anemia Secondaria a Chemioterapia

Groopman J.E. , Itri LM : Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 91: 1616–1634, 1999.

Cella D. , Zagari M.J. , Vandoros C. : Epoetin alfa treatment results in significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol, 21: 366–373, 2003.

Rizzo J.D. , Lichtin A.E. , Woolf S.H. : Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol, 20: 4083–4107, 2002.

Ludwig H. , Birgegard G. , Barrett-Lee P. : Prevalence and management of anemia in patients with hematologic malignancies and solid tumors: results from the European Cancer Anemia Survey (ECAS). Blood, 100: 234–235 (abstr), 2002.

Glaspy J. , Bukowski R. , Steinberg D. : Impact of therapy with epoetin alfa on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol, 15: 1218–1234, 1997.

Demetri G.D. , Kris M. , Wade J. : Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results of a prospective community oncology study. Procrit Study Group. J Clin Oncol, 16: 3412–3425, 1998.

Gabrilove J.L. , Cleeland C.S. , Livingston R.B. : Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol, 19: 2875–2882, 2001.

Littlewood T.J. , Bajetta E. , Nortier J.W. : Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo controlled study. J Clin Oncol, 19: 2865–2874, 2001.

Shasha D. , George M.J. , Harrison LB : Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer, 98: 1072–1079, 2003.

Littlewood T.J. , Nortier J. , Rapoport B. : Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol, 21: 169–180, 2003.

Cheung W. , Minton N. , Gunawardena K : Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol, 57: 411–418, 2001.

Zagari M. , Wacholtz M. , Xiu L : An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-containing chemotherapy. Proc EHA, abstract, 2003.

Witzig T.E. , Silberstein P.T. , Loprinzi C.L. : Phase III randomized double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol, 23: 2606–2617, 2005.

Demetri G.D. , Kris M. , Wade J. : Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol, 16: 3412–3425, 1998.

O'Shaughnessy J. , Vukelia S. , Savin M. : Impact of epoetin alfa on cognitive function, asthenia and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res Treat, 76: S138 (abst), 2002.

Buemi M. , Cavallaro E. , Floccari F. : Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci, 103: 275–282, 2002.

Teicher BA : Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am, 9: 475–506, 1995.

Fyles A.W. , Milosevic M. , Wong R. : Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol, 48: 149–156, 1998.

Chang J. , Couture F. , Young S. : Weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol, 23: 2597–2605, 2005.

Yellen S.B. , Cella D.F. , Webster K. : Measuring fatigue and other anemia related symptoms with the FACT measurement system. J Pain Sympt Manag, 13: 63–74, 1997.

Demetri GD : Anemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer, 84: 31–37 (Suppl), 2001.

Balducci L. , Extermann M : Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am, 14: 1–16, 2000.

Crawford J. , Cella D. , Cleeland C.S. : Relationship between changes in hemoglobin levels and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95: 888–895, 2002.

Richart J.M. , Petruska P.J. , Klebert K.S. : A phase III trial of epoetin alfa: early vs late administration in patients treated with chemotherapy. Blood, 100: 175b (abst), 2002.

Hudis C. , Williams D. , Gralow J. : Epoetin alfa maintains hemoglobin levels and quality of life in breast cancer patients receiving conventional adjuvant chemotherapy: final report. Proc ASCO, 22: 767 (abst), 2003.

Crawford J. , Robert F. , Perry M. : Epoetin alfa 40000 U once weekly maintains hemoglobin in advanced NSCLC patients receiving first-line chemotherapy. Anemia prevention in NSCLC Study Group. Proc ASCO, 22: 628 (abst), 2003.

Food and Drug Administration website: http://www.fda.gov/ohrms/dockets/ac/cder04.html#Oncologic.

Bohlius J. , Langensiepen S. , Schwarzer G. : Erythropoietin for patients with malignant disease (Cochrane Review). The Cochrane Library, Issue 2, 2005. Chichester, UK, John Wiley & Sons, Ltd.

Rizzo J.D. , Lichtin A.E. , Woolf S.H. : Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol, 20: 4083–4107, 2002.

Van Belle S.J. , Cocquyt V : Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol, 47: 1–11, 2003.

Bottini A. , Berruti A. , Brizzi M.P. : Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer, 89: 977–982, 2003.

Peters-Engl C. , Cassik P. , Schmidt I. : Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer. Acta Oncol, 44: 129–133, 2005.

Dammacco F. , Castoldi G. , Rodjer S : Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol, 113: 172–179, 2001.

Straus D.J. , Testa M. , Riggs S.A. : Early treatment with epoetin alfa improves anemia, quality of life and productivity in patients with hematologic malignancies and mild anemia during chemotherapy. Blood, 102 (11): abstr 1811, 2003.

Dammacco F. , Marschner R. , Gambacorta M : Epoetin alfa improves hemoglobin levels and quality of life parameters in anemic patients with hematologic malignancies receiving chemotherapy: interim analyses from the EPOLYM trial. 9th Congress of the European Hematology Association, Geneve, Switzerland, 10–13 June 2004.

Littlewood T.J. , Schenkel B. , Liss M : Effect of patient exclusion criteria on the efficacy of erythropoiesisstimulating agents in patients with cancer-related anemia. Oncologist, 10: 357–360, 2005.

Cazzola M. , Beguin Y. , Kloczko J. , Spicka I. , Coiffier B : Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production Br J Haematol, 122: 386–393, 2003.